Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15402180 | 0.90 | LMNA (0.42) | PTGDR2ALDH1A1HTTTSHRMEN1 | |
| SCHEMBL15375535 | 0.89 | TSHR (0.41) | PTGDR2ALDH1A1TDP1KDM4EHTT | |
| SCHEMBL15375490 | 0.83 | TDP1 (0.41) | PTGDR2ALDH1A1TDP1KDM4EHTT | |
| SCHEMBL15375431 | 0.80 | LMNA (0.41) | ALDH1A1TDP1HTTTSHRMEN1 | |
| SCHEMBL1539495 | 0.78 | TDP1 (0.40) | ALDH1A1TDP1KDM4EHTTTSHR | |
| SCHEMBL15375323 | 0.75 | TDP1 (0.46) | PTGDR2ALDH1A1TDP1KDM4EHTT | |
| SCHEMBL2236821 | 0.75 | FABP4 (0.46) | ALDH1A1TDP1HTTRXRARXRB | |
| SCHEMBL15375646 | 0.73 | LMNA (0.42) | PTGDR2ALDH1A1KDM4EHTTTSHR | |
| SCHEMBL1539465 | 0.73 | TDP1 (0.40) | ALDH1A1TDP1KDM4ETSHRRXRA | |
| SCHEMBL8897564 | 0.73 | FABP4 (0.61) | PTGDR2TDP1HTTRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2397459-B1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8624062-B2 | Method for producing phenylacetamide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295035-A1 | METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND | MRPL21, AADAC, ARSA | PTGDR2 938/4885ALDH1A1 1164/4885TDP1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.